The B-cell–depleting drug rituximab was associated with a twofold increased risk for infection in patients with relapsing-remitting multiple sclerosis (RRMS), regardless of treatment duration or whether patients had received other disease-modifying therapy (DMT) or had a short disease duration. “We found an approximately doubled risk of serious infections with rituximab compared with other DMTs…
